Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Eyenovia, Inc. (NASDAQ: EYEN).

Full DD Report for EYEN

You must become a subscriber to view this report.


Recent News from (NASDAQ: EYEN)

Eyenovia misses by $0.07
Eyenovia (NASDAQ: EYEN ): Q1 EPS of -$0.45 misses by $0.07 . Cash of $27.6M Press Release More news on: Eyenovia, Inc., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: May, 09 2018 06:41
Eyenovia Reports First Quarter 2018 Financial Results and Completion of EYN PG21 Study
NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced financial res...
Source: GlobeNewswire
Date: May, 09 2018 06:30
Eyenovia Announces Conference Call and Webcast for First Quarter 2018 Financial Results
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that the Co...
Source: GlobeNewswire
Date: April, 19 2018 08:30
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Eyenovia, Inc. Investors (EYEN)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Eyenovia, Inc. (NASDAQ: EYEN ) investors concerning the Company and its directors’ and officers’ possible violations of state laws. If you purchased Eyenovia   stock, have in...
Source: Business Wire
Date: April, 03 2018 20:31
Eyenovia Announces Fourth Quarter and Full Year 2017 Financial Results
NEW YORK, April 02, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced financial r...
Source: GlobeNewswire
Date: April, 02 2018 06:30
Eyenovia Appoints Three Industry Veterans to Board of Directors
NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that it has...
Source: GlobeNewswire
Date: March, 26 2018 16:05
Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full Year 2017 Financial Results
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”) (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, a...
Source: GlobeNewswire
Date: March, 19 2018 08:30
Eyenovia to Present at the 30th Annual ROTH Conference
NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”) (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, to...
Source: GlobeNewswire
Date: February, 27 2018 08:30
Eyenovia Advances MicroPine for Myopia into Phase III Clinical Development and Appoints Stanford Professor Dr. Douglas Fredrick to its Scientific Advisory Board and Myopia Program Steering Committee
NEW YORK, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”), (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, &...
Source: GlobeNewswire
Date: February, 21 2018 08:30
Premarket analyst action - healthcare
ResTORbio (NASDAQ: TORC ) initiated with Outperform rating and $36 (92% upside) price target at Leerink. Initiated with Buy rating and $23 price target at BofA/Merrill Lynch. Initiated with Outperform rating and $30 price target at Wedbush. More news on: resTORbio, Inc., Menlo Therapeutics...
Source: SeekingAlpha
Date: February, 20 2018 09:08

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-178.508.48818.508.487,987

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2066869196.6715Short
2018-08-1710,19710,49797.1420Short
2018-08-165031,30338.6032Short
2018-08-157271,12764.5075Short
2018-08-141002,1864.5746Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EYEN.


About Eyenovia, Inc. (NASDAQ: EYEN)

Logo for Eyenovia, Inc. (NASDAQ: EYEN)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: EYEN)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 09 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 30 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 30 2018
      Preliminary proxy statement providing notification matters to be brought to a vote
      Filing Type: PRE 14AFiling Source: edgar
      Filing Date: April, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 02 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: April, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 26 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 12 2018
      Filing by person(s) reporting owned shares of common stock in a public company >5%
      Filing Type: SC 13DFiling Source: edgar
      Filing Date: February, 21 2018

       

       


      Daily Technical Chart for (NASDAQ: EYEN)

      Daily Technical Chart for (NASDAQ: EYEN)


      Stay tuned for daily updates and more on (NASDAQ: EYEN)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: EYEN)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EYEN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of EYEN and does not buy, sell, or trade any shares of EYEN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/